AprilBio Co.,Ltd. (KOSDAQ:397030)
South Korea · Delayed Price · Currency is KRW 21,300
+1,100 (5.45%)
At close: Oct 1, 2026
AprilBio Revenue
AprilBio had revenue of 725.35M KRW in the twelve months ending June 30, 2026, down -91.92% year-over-year. In the year 2025, AprilBio had annual revenue of 2.17B, down -92.11%.
Revenue (ttm)
725.35M
Revenue Growth
-91.92%
P/S Ratio
807.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
585.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.17B | -25.34B | -92.11% |
| Dec 31, 2024 | 27.51B | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 200.00M | -23.20B | -99.15% |
| Dec 31, 2021 | 23.40B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 124.81B |
| ROKIT Healthcare | 32.81B |
| Genome & Company | 24.46B |
| JS Link | 22.78B |
| S.Biomedics | 16.49B |
| Qurient | 7.07B |
| IntoCell | 3.19B |
| Inventage Lab | 2.47B |